Head-down posture induces PERG alterations in early glaucoma

低头姿势会诱发早期青光眼患者的视觉诱发电位(PERG)改变

阅读:1

Abstract

PURPOSE: To probe susceptibility of retinal ganglion cells (RGC) to physiological stressors associated with moderate head-down body tilt in patients with suspicion of glaucoma or early manifest glaucoma (EMG). METHODS: One hundred nine subjects with best corrected visual acuity (BCVA) ≥ 20/20 and no disease other than glaucoma [glaucoma suspects (GS)=79, EMG=14, normal controls (NC)=16 and comparable age range were tested. Noncontact intraocular pressure (IOP), pattern electroretinogram (PERG), and brachial blood pressure/heart rate measurements were performed in 3 consecutive conditions (∼0038 min apart): seated (baseline), -10-degree whole body head-down tilt (HDT), and seated again (recovery). PERG amplitude and latency, IOP, and systolic/diastolic blood pressures, heart rate, calculated mean central retinal artery pressure, ocular perfusion pressure, and systolic/diastolic perfusion pressures were evaluated. RESULTS: During HDT, IOP significantly (P<0.001) increased in all groups approximately to the same extent (approximately 20%). PERG amplitude did not change in NC but decreased significantly (P<0.001) in patients (GS, -25%, EMG -23%). PERG phase become delayed in NC (-1.6%, P=0.04) but more so in patients (GS, -2.7%, P<0.001; EMG, -6.0%, P<0.001). The proportion of patients with PERG alterations significantly (P<0.05) exceeding those occurring in age-adjusted and baseline-adjusted NC were, GS: amplitude 20%, phase 15%; EMG: amplitude 14%, phase 50%. All measures recovered baseline values after HDT. CONCLUSIONS: Moderate HDT induces temporary worsening of RGC function in a subpopulation of GS and EMG patients. This noninvasive protocol may help disclose abnormal susceptibility of RGCs in a subset of the patients at risk of glaucoma.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。